Feeds

UK drugs trial hospitalises six

Intensive care for 'seriously ill' men

Secure remote control for conventional and virtual desktops

Six drug trial volunteers who were given an anti-inflammatory drug at a private research unit based at London's Northwick Park Hospital are in intensive care after suffering a "reaction", the BBC reports.

The six were given TGN1412 - "designed to treat conditions such as rheumatoid arthritis and leukaemia" - on Monday. Within hours they were hospitalised after suffering "an inflammatory response which affects some organs of the body", as Northwick's intensive care director Ganesh Suntharalingam put it.

Suntharalingam explained that two of the men were in a critical condition, while the remainder were "serious but showing some signs of improvement".

The girlfriend of one of the men described her 28-year-old boyfriend's face as so swollen he "looks like the Elephant Man". Myfanwy Marshall told the BBC: "His friends cannot even face seeing him. I have to stay there because I'm looking beyond all the wires and the puffiness. This is not leukaemia, this is not pneumonia, this is not something they know how to deal with."

Parexel, the firm behind the trial, said it had followed guidelines and that such cases were extremely rare. The company's Professor Herman Scholtz said: "When the adverse drug reaction occurred, the Parexel clinical pharmacology medical team responded swiftly to stop the study procedures immediately."

The drug's German-based manufacturer, TeGenero, said the reactions were "completely unexpected and did not reflect results from initial laboratory studies".

The Medicines and Healthcare products Regulatory Agency (MHRA), meanwhile, immediately withdrew the trial's authorisation and issued an international warning against testing. Its inspectors have visited the unit and are consulting the local health authority, Department of Health and police with regard to the matter.

According to the BBC, the drug had already been tested on animals and cleared for human trials. ®

Next gen security for virtualised datacentres

More from The Register

next story
Gigantic toothless 'DRAGONS' dominated Earth's early skies
Gummy pterosaurs outlived toothy competitors
Vulture 2 takes a battering in 100km/h test run
Still in one piece, but we're going to need MORE POWER
TRIANGULAR orbits will help Rosetta to get up close with Comet 67P
Probe will be just 10km from Space Duck in October
Boffins ID freakish spine-smothered prehistoric critter: The CLAW gave it away
Bizarre-looking creature actually related to velvet worms
CRR-CRRRK, beep, beep: Mars space truck backs out of slippery sand trap
Curiosity finds new drilling target after course correction
'Leccy racer whacks petrols in Oz race
ELMOFO rakes in two wins in sanctioned race
What does a flashmob of 1,024 robots look like? Just like this
Sorry, Harvard, did you say kilobots or KILLER BOTS?
NASA's rock'n'roll shock: ROLLING STONE FOUND ON MARS
No sign of Ziggy Stardust and his band
Why your mum was WRONG about whiffy tattooed people
They're a future source of RENEWABLE ENERGY
prev story

Whitepapers

5 things you didn’t know about cloud backup
IT departments are embracing cloud backup, but there’s a lot you need to know before choosing a service provider. Learn all the critical things you need to know.
Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
Build a business case: developing custom apps
Learn how to maximize the value of custom applications by accelerating and simplifying their development.
Rethinking backup and recovery in the modern data center
Combining intelligence, operational analytics, and automation to enable efficient, data-driven IT organizations using the HP ABR approach.
Next gen security for virtualised datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.